vs
Side-by-side financial comparison of Agilent Technologies (A) and Bath & Body Works, Inc. (BBWI). Click either name above to swap in a different company.
Agilent Technologies is the larger business by last-quarter revenue ($1.8B vs $1.6B, roughly 1.1× Bath & Body Works, Inc.). Agilent Technologies runs the higher net margin — 17.0% vs 4.8%, a 12.1% gap on every dollar of revenue. On growth, Agilent Technologies posted the faster year-over-year revenue change (7.0% vs -1.0%). Agilent Technologies produced more free cash flow last quarter ($175.0M vs $-1.0M). Over the past eight quarters, Agilent Technologies's revenue compounded faster (6.9% CAGR vs -26.0%).
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emissi...
Bath & Body Works, Inc. is an American specialty retail company based in Columbus, Ohio. It owns Bath & Body Works, posted $7.4 billion in revenue in 2023, and was listed as 481 on the 2024 Fortune 500 list of largest United States companies by revenue.
A vs BBWI — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.8B | $1.6B |
| Net Profit | $305.0M | $77.0M |
| Gross Margin | 52.6% | 41.3% |
| Operating Margin | 19.6% | 10.1% |
| Net Margin | 17.0% | 4.8% |
| Revenue YoY | 7.0% | -1.0% |
| Net Profit YoY | -4.1% | -27.4% |
| EPS (diluted) | $1.07 | $0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $1.6B | ||
| Q3 25 | $1.7B | $1.5B | ||
| Q2 25 | $1.7B | $1.4B | ||
| Q1 25 | $1.7B | $2.8B | ||
| Q4 24 | $1.7B | $1.6B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.6B | $1.4B |
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $77.0M | ||
| Q3 25 | $336.0M | $64.0M | ||
| Q2 25 | $215.0M | $105.0M | ||
| Q1 25 | $318.0M | $453.0M | ||
| Q4 24 | $351.0M | $106.0M | ||
| Q3 24 | $282.0M | $152.0M | ||
| Q2 24 | $308.0M | $87.0M |
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | 41.3% | ||
| Q3 25 | 51.1% | 41.3% | ||
| Q2 25 | 51.9% | 45.4% | ||
| Q1 25 | 53.5% | 46.7% | ||
| Q4 24 | 53.9% | 43.5% | ||
| Q3 24 | 54.2% | 41.0% | ||
| Q2 24 | 54.4% | 43.8% |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 10.1% | ||
| Q3 25 | 20.7% | 10.1% | ||
| Q2 25 | 18.0% | 14.7% | ||
| Q1 25 | 22.4% | 24.3% | ||
| Q4 24 | 24.0% | 13.5% | ||
| Q3 24 | 21.1% | 12.0% | ||
| Q2 24 | 23.1% | 13.5% |
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | 4.8% | ||
| Q3 25 | 19.3% | 4.1% | ||
| Q2 25 | 12.9% | 7.4% | ||
| Q1 25 | 18.9% | 16.3% | ||
| Q4 24 | 20.6% | 6.6% | ||
| Q3 24 | 17.9% | 10.0% | ||
| Q2 24 | 19.6% | 6.3% |
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $0.37 | ||
| Q3 25 | $1.18 | $0.30 | ||
| Q2 25 | $0.75 | $0.49 | ||
| Q1 25 | $1.11 | $2.06 | ||
| Q4 24 | $1.23 | $0.49 | ||
| Q3 24 | $0.97 | $0.68 | ||
| Q2 24 | $1.05 | $0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8B | $236.0M |
| Total DebtLower is stronger | $3.0B | $3.9B |
| Stockholders' EquityBook value | $6.9B | $-1.6B |
| Total Assets | $12.8B | $5.0B |
| Debt / EquityLower = less leverage | 0.44× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $236.0M | ||
| Q3 25 | $1.5B | $364.0M | ||
| Q2 25 | $1.5B | $636.0M | ||
| Q1 25 | $1.5B | $674.0M | ||
| Q4 24 | $1.3B | $191.0M | ||
| Q3 24 | $1.8B | $514.0M | ||
| Q2 24 | $1.7B | $855.0M |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $3.9B | ||
| Q3 25 | $3.4B | $3.9B | ||
| Q2 25 | $3.3B | $3.9B | ||
| Q1 25 | $3.3B | $3.9B | ||
| Q4 24 | $3.3B | $4.2B | ||
| Q3 24 | $2.1B | $4.2B | ||
| Q2 24 | $2.1B | $4.3B |
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $-1.6B | ||
| Q3 25 | $6.4B | $-1.5B | ||
| Q2 25 | $6.1B | $-1.5B | ||
| Q1 25 | $6.0B | $-1.4B | ||
| Q4 24 | $5.9B | $-1.7B | ||
| Q3 24 | $5.9B | $-1.7B | ||
| Q2 24 | $6.2B | $-1.7B |
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $5.0B | ||
| Q3 25 | $12.2B | $4.8B | ||
| Q2 25 | $12.2B | $4.9B | ||
| Q1 25 | $11.9B | $4.9B | ||
| Q4 24 | $11.8B | $5.0B | ||
| Q3 24 | $11.0B | $4.9B | ||
| Q2 24 | $10.9B | $5.2B |
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.53× | — | ||
| Q2 25 | 0.55× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.57× | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.34× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $268.0M | $80.0M |
| Free Cash FlowOCF − Capex | $175.0M | $-1.0M |
| FCF MarginFCF / Revenue | 9.7% | -0.1% |
| Capex IntensityCapex / Revenue | 5.2% | 5.1% |
| Cash ConversionOCF / Net Profit | 0.88× | 1.04× |
| TTM Free Cash FlowTrailing 4 quarters | $993.0M | $946.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $80.0M | ||
| Q3 25 | $362.0M | $-43.0M | ||
| Q2 25 | $221.0M | $188.0M | ||
| Q1 25 | $431.0M | $955.0M | ||
| Q4 24 | $481.0M | $-99.0M | ||
| Q3 24 | $452.0M | $-46.0M | ||
| Q2 24 | $333.0M | $76.0M |
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $-1.0M | ||
| Q3 25 | $259.0M | $-99.0M | ||
| Q2 25 | $107.0M | $151.0M | ||
| Q1 25 | $334.0M | $895.0M | ||
| Q4 24 | $388.0M | $-164.0M | ||
| Q3 24 | $360.0M | $-101.0M | ||
| Q2 24 | $230.0M | $30.0M |
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | -0.1% | ||
| Q3 25 | 14.9% | -6.4% | ||
| Q2 25 | 6.4% | 10.6% | ||
| Q1 25 | 19.9% | 32.1% | ||
| Q4 24 | 22.8% | -10.2% | ||
| Q3 24 | 22.8% | -6.6% | ||
| Q2 24 | 14.6% | 2.2% |
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 5.1% | ||
| Q3 25 | 5.9% | 3.6% | ||
| Q2 25 | 6.8% | 2.6% | ||
| Q1 25 | 5.8% | 2.2% | ||
| Q4 24 | 5.5% | 4.0% | ||
| Q3 24 | 5.8% | 3.6% | ||
| Q2 24 | 6.5% | 3.3% |
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | 1.04× | ||
| Q3 25 | 1.08× | -0.67× | ||
| Q2 25 | 1.03× | 1.79× | ||
| Q1 25 | 1.36× | 2.11× | ||
| Q4 24 | 1.37× | -0.93× | ||
| Q3 24 | 1.60× | -0.30× | ||
| Q2 24 | 1.08× | 0.87× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
BBWI
| Bath Body Works Stores | $1.2B | 77% |
| Bath Body Works Direct | $299.0M | 19% |
| Bath Body Works International | $73.0M | 5% |
